Intelence (Etravirine, TMC125)
The Latest
An Overview of Intelence (Etravirine)
Brand Name: Intelence Other Name(s): ETR Drug Class: Non-nucleoside Reverse Transcriptase Inhibitors
Etravirine (Intelence)
What Is Etravirine? Who Should Take It? What About Drug Resistance? How Is It Taken? What Are the Side Effects? How Does It React With Other Drugs?
What Is Etravirine?
Etravirine is a drug used as part of antiretroviral therapy (ART). I...
Intelence
Brand name: Intelence
Generic name: etravirine, or ETR
Class: Non-nucleoside reverse transcriptase inhibitor (non-nucleoside, NNRTI, or non-nuke)
Manufacturer: Janssen Therapeutics, www.intelence-info.com, (800) JANSSEN (526-7736)
AWP: $1,033.99/...
FAQs About Intelence (Etravirine)
Don't see your question? Ask it in our Choosing Your Meds forum or Managing Side Effects of HIV Treatment forum!
Basics | Drug Resistance | Side Effects
Basics
Can I take Intelence just once a day? What kind of meal should I eat before taking In...
New Warning of Serious Intelence Side Effect
In August 2009, the FDA announced an updated side effect warning for Intelence (etravirine), the newest approved NNRTI. This comes after reports of severe allergic reactions, usually occurring during the first 6 weeks of taking the drug in a small pe...
Tibotec, FDA Update Warning Label on HIV Drug's Risk of Severe Skin Reaction
Tibotec Therapeutics, a unit of Johnson & Johnson, "has strengthened a warning about serious skin reactions in patients treated with the company's HIV drug Intelence," the FDA and the company said on Wednesday, Reuters reports. Intelence has included...
News Analysis: U.S. Approval of Intelence (Etravirine)
On Jan. 18, the U.S. Food and Drug Administration (FDA) approved the first new non-nucleoside reverse transcriptase inhibitor (NNRTI) in nearly a decade. It was known throughout much of its development as TMC125, and is now known by its generic name,...
AIDS Activists Urge Tibotec to Expand Access to TMC125, Show Compassion for HIV Salvage Patients
Houston, TX -- AIDS Activists, seeking to expand access to new drugs for people living with HIV who have run out of treatment options, are urging Tibotec Pharmaceuticals, a subsidiary of Johnson and Johnson, to provide compassionate access to their T...
Waiting in the Wings: More New Drugs
2003 was a banner year for HIV drug approval despite the fact that some of the drugs are very similar to what already exists. Improvements in medical treatment come slowly and incrementally, but lately there seems to be a wave of new treatments that ...